RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis

Shou, Feiyan; Xu, Feng; Li, Gang; Zhao, Zhenhua; Mao, Ying; Yang, Fangfang; Wang, Hongming; Guo, Hangyuan

doi:10.2147/ott.s124417

Cited by 17 publications

(16 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified that the sensitivity value of methylated FAM19A4 and PLR value of methylated RASSF1A , FHIT , MGMT , and p16 are relatively high, suggesting that they are comprehensive parameters for the screening test [ 61 ]. In addition, methylated RASSF1A and p16 genes are reported to be promising driving molecules in many cancers under the concept of precision medicine [ 9 , 62 , 63 , 64 , 65 , 66 , 67 ]. In addition, the methylation of FAM19A4 , FHIT , and MGMT were reported to play important roles in the occurrence and deterioration of lung cancer [ 68 , 69 , 70 , 71 ].…”

Section: Discussionmentioning

confidence: 99%

The Indirect Efficacy Comparison of DNA Methylation in Sputum for Early Screening and Auxiliary Detection of Lung Cancer: A Meta-Analysis

Liu

Peng

Sun

et al. 2017

IJERPH

View full text Add to dashboard Cite

Background: DNA methylation in sputum has been an attractive candidate biomarker for the non-invasive screening and detection of lung cancer. Materials and Methods: Databases including PubMed, Ovid, Cochrane library, Web of Science databases, Chinese Biological Medicine (CBM), Chinese National Knowledge Infrastructure (CNKI), Wanfang, Vip Databases and Google Scholar were searched to collect the diagnostic trials on aberrant DNA methylation in the screening and detection of lung cancer published until 1 December 2016. Indirect comparison meta-analysis was used to evaluate the diagnostic value of the included candidate genes. Results: The systematic literature search yielded a total of 33 studies including a total of 4801 subjects (2238 patients with lung cancer and 2563 controls) and covering 32 genes. We identified that methylated genes in sputum samples for the early screening and auxiliary detection of lung cancer yielded an overall sensitivity of 0.46 (0.41–0.50) and specificity of 0.83 (0.80–0.86). Combined indirect comparisons identified the superior gene of SOX17 (sensitivity: 0.84, specificity: 0.88), CDO1 (sensitivity: 0.78, specificity: 0.67), ZFP42 (sensitivity: 0.87, specificity: 0.63) and TAC1 (sensitivity: 0.86, specificity: 0.75). Conclusions: The present meta-analysis demonstrates that methylated SOX17, CDO1, ZFP42, TAC1, FAM19A4, FHIT, MGMT, p16, and RASSF1A are potential superior biomarkers for the screening and auxiliary detection of lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

The Indirect Efficacy Comparison of DNA Methylation in Sputum for Early Screening and Auxiliary Detection of Lung Cancer: A Meta-Analysis

Liu

Peng

Sun

et al. 2017

IJERPH

View full text Add to dashboard Cite

show abstract

“…Its increased expression can mainly make tumor cells resistant to cisplatin (24). The aberrant methylation of RASSF1A gene serves an important role in the occurrence and development of various tumors, including bladder cancer and thyroid cancer (25,26), and is associated with drug resistance and tumor prognosis (27,28). The purpose of the present study was to detect the expression of drug resistance genes and aberrant methylation of RASSF1A in different types of ovarian tissues and to investigate their role in the primary resistance of ovarian cancer.…”

Section: Discussionmentioning

confidence: 98%

Multidrug resistance affects the prognosis of primary epithelial ovarian cancer

et al. 2019

View full text Add to dashboard Cite

Multidrug-resistant tumor cells can tolerate different structures, functions and antidrug action mechanisms, therefore, allowing these cells to respond to various structurally unrelated mechanisms of different chemotherapy drugs and to exhibit cross-resistance. The present study aimed to investigate the role of Multi-drug resistance gene (MDR1), Placental glutathione S-transferase-P1 (GSTP1), Lung resistance protein (LRP) and Ras association domain family member 1 (RASSF1A) in primary epithelial ovarian cancer (PEOC). The mRNA (protein) expression levels of MDR1, product P glycoprotein, LRP and GSTP1 were evaluated with reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis in all tissue samples, ovarian cancer cell line A2780 and A2780/DDP. Methylation-specific PCR (MSP) was used to detect RASSF1A gene methylation in all tissue samples. The resistance genes/proteins were either poorly or not expressed in A2780, however were highly expressed in A2780/DDP cell line. The expression of resistance genes/proteins decreased following different concentrations of zebularine-stimulated A2780/DDP. Hypermethylation and low expression of RASSF1A gene were detected in PEOC and A2780/DDP. Subsequent to being exposed to different concentrations of zebularine-stimulated A2780/DDP, the RASSF1A methylation level was decreased, while the unmethylation level was increased. The expression of RASSF1A gene/protein was gradually restored, and the gene/protein expression was enhanced with the increase in drug concentration. Multivariate logistic regression indicated that the expression level of gene LRP and GSTP1 was a risk factor for PEOC prognosis. Furthermore, the expression of LRP and GSTP1 in the negative-group survival curves was higher compared with the positive group. High expression of resistance genes may serve an important role in cancer primary resistance. Low expression caused by hyper-methylation of RASSF1A gene may serve an important role in cancer-acquired resistance in PEOC. The present study suggested that resistant gene expression may be a potential prognostic biomarker.

show abstract

“…The hypermethylation of TSG promoter suppresses genes expression by inhibiting transcription, thereby affecting cell signaling pathways. Two previous meta-analyses demonstrated the association between RASSF1A promoter methylation and PTC risk [ 31 , 41 ]. In the current report, a comprehensive review was carried out to determine the relationship between thyroid cancer susceptibility and gene methylation.…”

Section: Discussionmentioning

confidence: 99%

“…In some studies, RASSF1 promoter inactivation has been detected in more than 30% of thyroid tumors, representing the most and frequent event in thyroid cancers [ 72 , 73 ]; however, in some reports, no significant correlation between RASSF1 methylation and thyroid cancer risk was detected [ 68 , 74 – 78 ]. In two prior meta-analyses, researchers only examined the association between RASSF1 promoter methylation and PTC risk [ 31 , 41 ]. Although the results of these prior meta-analyses demonstrated that the frequency of RASSF1 promoter methylation was significantly associated with increased risk of thyroid cancer, our study showed that the influence of RASSF1 promoter methylation was lower than those of CDH1 and SLC5A8 promoter methylation.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer

et al. 2017

View full text Add to dashboard Cite

Promoter methylation in a number of tumor-suppressor genes (TSGs) can play crucial roles in the development of thyroid carcinogenesis. The focus of the current meta-analysis was to determine the impact of promoter methylation of eight selected candidate TSGs on thyroid cancer and to identify the most important molecules in this carcinogenesis pathway. A comprehensive search was performed using Pub Med, Scopus, and ISI Web of Knowledge databases, and eligible studies were included. The methodological quality of the included studies was evaluated according to the Newcastle Ottawa scale table and pooled odds ratios (ORs); 95% confidence intervals (CIs) were used to estimate the strength of the associations with Stata 12.0 software. Egger’s and Begg’s tests were applied to detect publication bias, in addition to the “Metatrim” method. A total of 55 articles were selected, and 135 genes with altered promoter methylation were found. Finally, we included eight TSGs that were found in more than four studies (RASSF1, TSHR, PTEN, SLC5A, DAPK, P16, RARβ2, and CDH1). The order of the pooled ORs for these eight TSGs from more to less significant was CDH1 (OR = 6.73), SLC5 (OR = 6.15), RASSF1 (OR = 4.16), PTEN (OR = 3.61), DAPK (OR = 3.51), P16 (OR = 3.31), TSHR (OR = 2.93), and RARβ2 (OR = 1.50). Analyses of publication bias and sensitivity confirmed that there was very little bias. Thus, our findings showed that CDH1 and SCL5A8 genes were associated with the risk of thyroid tumor genesis.

show abstract

RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis

Cited by 17 publications

References 42 publications

The Indirect Efficacy Comparison of DNA Methylation in Sputum for Early Screening and Auxiliary Detection of Lung Cancer: A Meta-Analysis

The Indirect Efficacy Comparison of DNA Methylation in Sputum for Early Screening and Auxiliary Detection of Lung Cancer: A Meta-Analysis

Multidrug resistance affects the prognosis of primary epithelial ovarian cancer

Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer

Contact Info

Product

Resources

About